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Michael J. Davidson, MDnTranscatheter aortic valve replacement (TAVR) hasemerged as the standard treatment for patients with
aortic valve stenosis who will beneﬁt from aortic valve
replacement but are inoperable or at extremely high risk for
traditional surgical aortic valve replacement.1,2 The Edwards
Sapien balloon expandable valve (Edwards Lifescience,
Irvine, CA) is the ﬁrst transcatheter valve approved by the
United States Food and Drug Administration (FDA) for
TAVR. Several other valve designs, predominantly self-
expanding, have been in clinical trial use in the United States
and are not yet approved by the FDA. The one with the
greatest clinical experience, and the ﬁrst self-expanding valve
to gain FDA approval, is the Medtronic Corevalve (Med-
tronic, Inc, Minneapolis, MN).
The ﬁrst choice for TAVR access is transfemoral (TF), but
the large sheath required for valve insertion limits the use of
this approach to patients with acceptable iliofemoral
anatomy. In the largest randomized control study of TAVR,
the Placement of Aortic Transcatheter Valves trial, up to 30%
of patients were not suitable for TF approach.2 For the
currently approved TF Sapien system, a 22-F (25-F outer
diameter, 8.5 mm) sheath is required for placement of the
23-mm valve and a 24-F (28-F outer diameter, 9.3 mm) is
required for the 26-mm valve. Smaller vessel size, tortuous
arteries or excessive calciﬁcation, and severe aortic athero-
sclerotic disease or tortuosity are contraindications for the
TF approach. The initial alternative described was a
transapical (TA) approach through left ventricular (LV) apex
via limited thoracotomy;3 however, the TA approach has
been associated with a higher complication rate compared
with that of surgical aortic valve replacement.4 This
prompted a search for alternative nonfemoral access
strategies. These have included direct transaortic (TAo),matter r 2013 Elsevier Inc. All rights reserved.
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device, transaxillary. Of these, the TAo has emerged as the
dominant alternative access approach compared with TF or
TA. This approach, though widely used, was originally
considered “off label” as it was not part of the original FDA
approval for the Edwards Sapien device. It is a recognized
usage in the ongoing trials of the Edwards Sapien and
Medtronic Corevalve devices.
The TAo approach is performed through either right
anterior thoracotomy or upper hemisternotomy,5-7 and it
avoids any manipulation of the myocardium, which is
arguably a disadvantage of the TA approach. It accesses
directly through the aorta, which is a more familiar technique
in cardiac surgery than ventriculotomy and is generally
associated with fewer complications. We describe our strategy
of patient selection and preoperative evaluation as well as the
procedural steps of TAo TAVR. We have focused on the
Edwards Sapien system as our experience is predominantly
with this device. That said, many of the procedural and
evaluation steps are pertinent to other systems as well.Patient Selection and
Preoperative Screening
All patients considered as candidates are assessed by
multidisciplinary team consisting of cardiac surgeons,
interventional cardiologists, and echocardiographers. Inop-
erability is a consensus decision of the team including
concurrence by 2 cardiothoracic surgeons. Preoperative
evaluation consists of transthoracic or transesophageal
echocardiogram (TEE), or a combination of both, coronary
angiogram, and electrocardiogram-gated 3-dimentional mul-
tidetector computed tomography (3-D MDCT) of the chest,
abdomen, and pelvis. Postprocessing of CT angiography data
allows precise assessment of aortic annular dimensions,
quality, location and tortuosity of the aorta, and diameter
and course of iliac and femoral vessels. In patients with renal
insufﬁciency, we use a combination of noncontrast CT and
intravascular ultrasound performed at the time of coronary
angiography to evaluate vessel size and calciﬁcation.
Accurate sizing of the aortic annulus is critical for
procedural success. Excessive oversizing of the valve can
cause aortic rupture and undersizing can cause paravalvular
leak and valve dislodgement. Three-dimensional MDCT275
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than echocardiographic measurements and is the current
clinical standard. Three-dimensional electrocardiographically
gated MDCT should be obtained, and reconstruction of the
valve should be orthogonal to the central axis of the LV
outﬂow tract. We use multiplanar rendering software to align
the axis in axial, coronal, and sagittal planes. This allows the
planar measurement of annular diameter and valve area.
The 3-D MDCT data are also reviewed with particular
attention to (1) location of calcium or atheromatous disease
in the aorta, (2) distance from the sternum to the aotic target
entry site, (3) relationship between the axis of the aorta and
axis of skin incision and aortic entry site, and (4) distance
between aortic entry site and the annulus (450 mm is
required for the full expansion of the balloon at the time of
valve deployment). Contraindications to the TAo approach
include a porcelain aorta, inadequate distance between aortic
entry site and the aortic annulus, and severe chronic obstruc-
tive pulmonary disease that is believed to preclude recovery
from thoracotomy. Relative contraindications include a
hostile chest (such as bypass grafts in jeopardy from uppersternotomy) or signiﬁcant adhesions in the right pleural
space or both.
There are 2 strategies for the TAo approach: right anterior
thoracotomy through the second intercostal space or upper
hemisternotomy in J-fashion to second or third intercostal
space. Our preference is to perform right anterior thoracot-
omy as this approach avoids sternotomy, decreases trauma,
and is less likely to jeopardize bypass grafts in reoperative
situations. We perform upper hemisternotomy in situations
where there is a deep aorta (46 cm from the sternum) or
one shifted toward the left, in case of previous right lung
surgery, or in patients in whom sheath insertion cannot be
coaxial if right anterior thoracotomy is chosen.
Procedures are performed in the hybrid operating room
with a high-quality ﬁxed ﬂuoroscopy system. The patient is
placed in supine position. General anesthesia with endo-
tracheal intubation is performed. We place a pulmonary
artery catheter for exceptionally high-risk cases such as those
with low ejection fraction or severe pulmonary hypertension.
TEE is performed to guide valve placement and to monitor
the patient during the case (Figs. 1-7).
Procedural Steps
Line of
sternotomy
A
Figure 1 (A) Upper hemisternotomy approach. Midline incision to the level of the third intercostal space is made. The sternum is divided in
J-fashion using a standard oscillating saw to the third intercostal space.
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Figure 1 (Continued) (B) A sternal retractor is used and the pericardium is opened. Following placement of pericardial sutures, the retractor is
removed and the pericardial sutures are tied to the skin. This mobilizes the aorta up into the ﬁeld. The sternal retractor is placed and the aorta
is inspected. Epicardial ultrasound can be used from the upper sternotomy approach to further evaluate the ascending aorta.
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Line for right anterior
minithoracotomy in 2nd
intercostal space
A
Figure 2 (A) Right thoracotomy approach. For the right anterior thoracotomy approach, the right second intercostal space is marked and an
incision of 4-5 cm is made lateral to the sternal edge.
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Figure 2 (Continued) (B) The pectoralis muscles are split and intercostal muscles divided at the upper edge of the third rib. The pleural space is
entered cautiously with anticipation of adhesions if the patient has had previous cardiac surgery. The intercostals are divided beyond the skin
incision both medially and laterally; a generous intercostal incision allows rib spreading without fracture. The right internal mammary artery
and vein are either retracted or ligated, though generally they can be spared.
Ascending aorta
Pericardium
Figure 3 Use of soft tissue retractor and obtaining peripheral vascular access. We prefer to use an Alexis wound protector or retractor (Applied
medical Technology, Brecksville, OH) to aid in exposure from the right thoracotomy approach. If the exposure is inadequate with the Alexis, a
rib retractor is placed. The location of the phrenic nerve is conﬁrmed at this point to avoid injury. Thymic fat is divided, and the pericardium
is opened parallel to the nerve. Multiple retraction sutures are placed to expose the aorta. It is difﬁcult to perform epicardial ultrasound of the
aorta from the right thoracotomy approach, though the aorta would have been evaluated preoperatively with the CT angiography and
signiﬁcant atherosclerotic disease excluded.
Sheaths that are 5 or 6 F in dimension are placed in the common femoral artery and vein. A temporary transvenous pacing lead is
positioned via the venous sheath and appropriate pacing capture assured. An angled pigtail catheter is advanced to the aortic root and root
aortography performed to determine the appropriate ﬂuoroscopic angle for imaging the aortic annulus in a perpendicular plane. This is a
critical step for precise valve deployment and the team must ensure that the ideal angle is obtained.
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Figure 4 Placement of aortic purse-string suture. Fluoroscopy is performed to conﬁrm the correct puncture site and its relationship to the
annulus. The size of the sheath is conﬁrmed before making a purse-string suture in the aorta as the purse-string suture for the sheath is made
larger than the standard purse-string suture used for a conventional aortic perfusion cannula. We prefer to place 2 diamond purse-string
sutures using 2-0 Ti.Cron suture (Covidien, Mansﬁeld, MA) with one with large pledgets in right-left direction and one in the cranial-caudal
direction. Rommel tourniquets are used to secure these sutures.
T. Kaneko et al.282
Sheath introduced
over guide wire
A
Figure 5 (A) Sheath placement. Following the placement of purse-string sutures in the aorta and after obtaining peripheral vascular access,
heparin is administered. We begin with 70 U/kg of unfractionated heparin and monitor activated clotting time with a target of 250-300
seconds.
Multiple methods have been described for sheath placement in the ascending aorta as there is no procedure-speciﬁc sheath designed for
TAo access. Some centers have used the TF sheath, others have used the TA sheath (Ascendra), and yet others have used various
modiﬁcations of other access devices that can accommodate the delivery catheter. We prefer to use a TF sheath (Retroﬂex 3 introducer sheath)
instead of TA sheath (Ascendra 3 sheath) as the TF sheath has smaller outer diameter (8.4 mm for 23-mm valve and 9.2 mm for 26-mm valve
in Retroﬂex vs 9.9 mm in Ascendra) and minimizes the access size in the aorta. On the contrary, the TF sheath is longer and has a hydrophilic
coating, which may make manipulation more difﬁcult. We place a number 5 silk tie approximately 1 cm from the tip of the sheath to act as a
“bumper” and aid in positioning in the aorta.
An 18-gauge needle is used to puncture the ascending aorta at the center of the purse-string suture, and a J-shaped 0.035-in soft guidewire
and a 5- or 6-F short sheath is introduced in the ascending aorta. A Berenstein catheter is used to direct a straight guidewire through the aortic
valve and into the LV. The Berenstein catheter is used to exchange out the straight wire for a 0.035-in/1-cm tip Amplatz Extra-Stiff guidewire,
with its coiled tip in the LV apex. The 6-F short sheath is removed and the valve delivery sheath is then advanced under ﬂuoroscopy into the
aorta over the Amplatz wire; 1-2 cm of the sheath at the tip is usually inserted in the ascending aorta, though the dilator generally traverses the
valve into the LV, and care must be taken not to cause trauma to the ventricle.
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Sheath secured in place between
snared Rommel tourniquet
B
Figure 5 (Continued) (B) The dilator is withdrawn and the sheath is secured by a Rommel tourniquet and held in place by large silk sutures
around the sheath and tourniquet.
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Tip of sheath in
ascending aorta
Figure 6 Preparation for valve deployment. In most cases, predilation of the native aortic valve is achieved by balloon aortic valvuloplasty
(BAV). The purpose of BAV is to assure that native valve is amenable to TAVR and to allow easier passage of the device. A simultaneous root
angiogram at the time of BAV can be a conﬁrmatory test for annular sizing and to assess the distance from annulus to the coronary ostia. BAV
also allows testing of rapid ventricular pacing and determination adequate rate to eliminate the cardiac output before the critical ﬁnal valve
deployment.
BAV is performed as previously described and does not differ from TA or TF approach.3 Generally a 20-mm balloon is used before
deployment of a size 23 Sapien valve and a 23-mm balloon used for the size 26-mm Sapien valve. One must be prepared for the possibility of
severe aortic insufﬁciency, which may require prompt deployment of the prosthetic valve.
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Placement & expansion of
replacement aortic valve
Figure 7 Valve deployment. The delivery balloon is prepared with a mixture of 1:4 contrast to saline, and the valve is then crimped onto the delivery
balloon according to the manufacturer's instructions. This is done shortly before the deployment to limit to time of the valve in crimped state, which
may damage the leaﬂets. The mounted device is placed into a loader. At least 2 members of the team conﬁrm correct orientation before insertion.
Once the valve is advanced out of the sheath, it cannot be withdrawn back in to the aorta; hence, it is critical to maintain wire position in the LV.
The system is passed across the native valve and the delivery catheter “pusher” is retracted. Care must be taken when advancing the delivery catheter
in patients with small ventricular cavity size as the LV can be perforated even with the guidewire in an appropriate position. Root angiography is
performed to conﬁrm the correct position of the annulus and the calcium landmarks. We use the “50:50 rule”—50% of the valve should be above
the annulus and 50% below.
Ventilation is held to minimize movement, rapid ventricular pacing is initiated and the deployment balloon is inﬂated slowly and held for several
seconds at full volume to allow proper valve expansion. The valve placement is performed in a slow stepwise manner to allow controlled and ﬁne
repositioning during balloon inﬂation. Rapid ventricular pacing is critical and early termination or missed capture of pacing can eject the valve into
the aorta. At the same time, the team must be aware that following prolonged ventricular pacing, the patient may develop hemodynamic instability
or complete heart block. Pharmacologic support as well as VVI pacing at appropriate physiological rates can be performed in these cases.
If urgent bypass support is needed at any point during the procedure, the aorta can be directly cannulated or percutaneous femoral arterial
cannulation may be performed. One of the femoral venous sheaths can be upsized to a venous cannula should the need for urgent bypass arise.
A rapid TEE assessment is performed to assure proper valve position and paravalvular leak. The presence of paravalvular leak without central
leak may necessitate reballooning of the valve. The guidewire can be removed if central and paravalvular leak is difﬁcult to differentiate. If
reballooning is required, this must also be performed under rapid ventricular pacing and care must be taken not to overexpand the distal (aortic)
end of the stent, which may cause leaﬂet malcoaptation. Completion root angiography may be performed to demonstrate valve position, to
demonstrate the degree of any aortic insufﬁciency, and to conﬁrm coronary ﬂow.
After successful valve deployment, the delivery sheath is removed under rapid ventricular pacing. Two purse-string sutures are tied and
additional full-thickness pledgeted 2-0 Ti.Cron suture is placed in a horizontal mattress. Protamine may be given to reverse the heparin.
If cardiac conduction is preserved (or if there is a permanent indwelling pacemaker), the temporary pacemaker lead is removed. The femoral
sheaths are removed, with the use of closure devices or manual pressure at operator discretion. TEE assessment is performed at this point to ensure
there is no pericardial effusion as in some cases effusions may not be visualized through the small pericardial opening.
For right anterior thoracotomy, after conﬁrming hemostasis, a chest drain is inserted from ﬁfth or sixth intercostal space and placed in the right
pleural space. The pericardium is left open. The second interspace must be properly secured to prevent future lung herniation. We prefer to use a
Gore-tex patch (Gore medical, Flagstaff, AZ) and secure this to the second and third ribs. The incision is closed in layers with absorbable suture.
For upper hemisternotomy, a 16-F blake drain is placed in the pericardial space. The sternum is closed with multiple sternal wires, and the
incision is closed in layers.
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The patient is extubated in the operating room whenever
possible. Patients who have delayed emergence, inadequate
ventilatory mechanics, or require hemodynamic monitoring
must remain intubated. All patients are sent to the Cardiac
Intensive Care Unit overnight for recovery and are
monitored for possible complications including heart block,
myocardial ischemia from coronary obstruction, postoper-
ative bleeding, access site hematoma, and paravalvular leak.
A pulmonary artery catheter, if used, is removed
immediately unless the patient has low cardiac output,
signiﬁcant pulmonary hypertension, or requires inotropic
support. On the following morning, the patient is given
81 mg of oral aspirin and 75 mg of clopidogrel. Typically,
chest tubes and urinary catheters are removed and patients
sent to the stepdown unit on postoperative day 1.Conclusion
TAVR has emerged as the dominant treatment for aortic valve
stenosis in patients who are poor candidates for surgical valve
replacement. Although TF access is preferred to decrease
invasiveness, it is not appropriate in a large percentage of
patients due to poor iliofemoral or aortic anatomy. Newer
devices with smaller sheath proﬁles will allow a larger
percentage of patients to receive a TF approach; the current
investigational devices can be inserted through 14-F sheaths.
Nevertheless, there will always be a patient population with
anatomy that is prohibitive to a TF approach. Although the TA
approach used during the original Placement of Aortic Trans-
catheter Valves trial continues to be a useful option, it carries a
number of pitfalls related to large-bore myocardial access.
The TAo approach represents an important access technique
for patients in whom the TF approach is not possible. It avoids
some of the disadvantages and difﬁculties of the TA approach
by not directly manipulating the myocardium. Moreover,
access of the aorta is familiar to all cardiac surgeons and can beaccomplished more readily in most hands than LV apical
access. Ultimately, the decision between TAo and TA would be
based on weighing relevant clinical factors. Findings such as
LV dysfunction, apical thrombus, or severe hypertrophy
would tend to favor a TAo approach over TA, whereas others
such as porcelain aorta would favor TA. There have been no
randomized studies comparing both the approaches, so no
formal recommendation can be made in the absence of clinical
factors favoring one over the other. Though we have preferred
the TAo approach for its simplicity, further investigation is
clearly needed.
Compulsive preoperative assessment, team coordination,
and effective communication are the keys to the success of
this procedure. Though the TAo approach is a distinctly
“surgical” procedure compared with TF, we feel strongly that
these procedures be performed by the integrated heart team
to maximize success.References
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